Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses.Cells · 2020
   Review
2. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.Neoplasia (New York, N.Y.) · 2018
   Article
3. Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.Journal of clinical medicine research · 2016
   Review
4. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas.Current genomics · 2011
   Article
5. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.The Journal of clinical endocrinology and metabolism · 2011
   Article

Corrections and comments

• Comment on
  RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.2009

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as